Mozart Therapeutics, a Seattle-based biotech centered on developing CD8 treg modulators to treat autoimmune and inflammatory diseases, has raised $25 million from new investors to extend its Series A. Mozart’s existing investors include Sofinnova Partners, Eli Lilly & Company, ARCH Venture Partners, Merck’s MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments.
The new funds bring Mozart’s total raise to $80 million, with names such as Pfizer Ventures, AbbVie Ventures, UPMC Enterprises and Ono Venture Investment participating in the extension. Mozart’s pipeline currently includes several CD8 treg modulators, including its MTX-101 candidate, designed to treat autoimmune diseases. The biotech expects to file an IND and start a Phase I trial for MTX-101 in 2024.
“We have made significant progress toward our mission of developing disease-modifying therapeutics that restore immune balance, and this additional capital will help support the advancement of our lead candidate, MTX-101, into…
Click here to view original post